Table 4.
Spearman correlation coefficients among methylation levels and clinical characters for TD (above diagonal) and NTD (below diagonal)
| Variable | CYP2E1 site 1 | CYP2E1 site 2 | CYP2E1 site 3 | CYP2E1 average | Age | Duration | PANSST | PANSSP | PANSSN | PANSSG | AIMS |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CYP2E1 site 1 | 1.000 | 0.740*** | 0.809*** | 0.908*** | − 0.042 | 0.158 | − 0.016 | − 0.074 | − 0.053 | 0.113 | 0.070 |
| CYP2E1 site 2 | 0.955*** | 1.000 | 0.785*** | 0.910*** | 0.105 | 0.216 | − 0.025 | − 0.085 | − 0.030 | 0.126 | 0.294* |
| CYP2E1 site 3 | 0.983*** | 0.970*** | 1.000 | 0.851*** | 0.022 | 0.135 | − 0.004 | − 0.114 | − 0.092 | 0.224 | 0.233 |
| CYP2E1 average | 0.993*** | 0.977*** | 0.987*** | 1.000 | 0.121 | 0.294* | − 0.040 | − 0.067 | − 0.096 | 0.128 | 0.263 |
| Age | 0.141 | 0.031 | 0.126 | 0.106 | 1.000 | 0.776*** | − 0.027 | 0.128 | − 0.080 | − 0.083 | 0.265 |
| Duration | 0.178 | 0.056 | 0.152 | 0.142 | 0.884*** | 1.000 | 0.073 | 0.132 | 0.069 | − 0.073 | 0.173 |
| PANSST | − 0.061 | − 0.024 | − 0.006 | − 0.062 | − 0.162 | − 0.152 | 1.000 | 0.832*** | 0.764*** | 0.796*** | − 0.227 |
| PANSSP | 0.231 | 0.184 | 0.233 | 0.219 | 0.046 | − 0.152 | 0.703*** | 1.000 | 0.455* | 0.609** | − 0.223 |
| PANSSN | − 0.238 | − 0.170 | − 0.193 | − 0.225 | − 0.215 | − 0.247 | 0.641*** | 0.192 | 1.000 | 0.384* | − 0.156 |
| PANSSG | − 0.050 | 0.013 | 0.012 | − 0.031 | − 0.298* | − 0.308* | 0.711*** | 0.479** | 0.264 | 1.000 | − 0.029 |
| AIMS | – | – | – | – | – | – | – | – | – | – | 1.000 |
PANSS refers to positive and negative syndrome scale; PANSST refers to the total score; PANSSP refers to positive score; PANSN refers to negative score; PANSSG refers to the general psychopathology score; AIMS refers to abnormal involuntary movement scale; AIMSS refers to AIMS score. * refers to p ≤ 0.05, ** refers to p < 0.01, *** refers to p < 0.001 in Spearman correlation analysis